Richard Bartram

Currently holds a position at Esperion Therapeutics Inc

Position	Company	Period
Chief Financial Officer	Esperion Therapeutics Inc	Jan. 1, 2018 -
Vice President - Finance	Esperion Therapeutics Inc	None -

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2026-06-10	2026-06-10	MBX Biosciences Inc (MBX)	PrS Proposed sale	76,218 425.30 US$3,369,548	76,218	425.30	US$3,369,548
2026-06-09	2026-06-09	MBX Biosciences Inc (MBX)	PrS Proposed sale	80,025 383.73 US$1,363,658	80,025	383.73	US$1,363,658
2026-06-09	2026-06-09	MBX Biosciences Inc (MBX)	PrS Proposed sale	67,472 398.24 US$3,098,788	67,472	398.24	US$3,098,788
2026-05-13	2026-05-13	MBX Biosciences Inc (MBX)	PrS Proposed sale	15,000 36.95 US$554,296	15,000	36.95	US$554,296
2026-05-11	2026-05-11	MBX Biosciences Inc (MBX)	PrS Proposed sale	22,500 44.08 US$991,901	22,500	44.08	US$991,901
2026-05-08	2026-05-08	MBX Biosciences Inc (MBX)	PrS Proposed sale	10,000 37.96 US$379,562	10,000	37.96	US$379,562
2026-05-07	2026-05-07	MBX Biosciences Inc (MBX)	PrS Proposed sale	10,000 32.21 US$322,050	10,000	32.21	US$322,050
2026-05-01	2026-05-01	MBX Biosciences Inc (MBX)	PrS Proposed sale	5,000 31.80 US$159,000	5,000	31.80	US$159,000
2026-04-22	2026-04-22	MBX Biosciences Inc (MBX)	PrS Proposed sale	10,423 32.75 US$341,378	10,423	32.75	US$341,378
2026-03-25	2026-03-25	MBX Biosciences Inc (MBX)	PrS Proposed sale	1,061 28.48 US$30,217	1,061	28.48	US$30,217
2026-03-16	2026-03-16	MBX Biosciences Inc (MBX)	PrS Proposed sale	10,000 30.05 US$300,471	10,000	30.05	US$300,471